Core Viewpoint - Abivax SA has successfully completed an offering of American Depositary Shares (ADSs), raising gross proceeds of approximately $747.5 million (€637.5 million) following the full exercise of the underwriters' option to purchase additional ADSs [1][2]. Group 1: Offering Details - The offering included a total of 11,679,400 ADSs, with gross proceeds of approximately $747.5 million (€637.5 million) and estimated net proceeds of around $700.3 million (€597.2 million) after deducting underwriting commissions and offering expenses [2]. - The offering price for the additional ADSs was set at $64.00 per ADS, which corresponds to €54.58 per ordinary share, reflecting a premium of 21.0% over the volume weighted average price of the ordinary shares in the preceding trading sessions [4]. Group 2: Use of Proceeds - The company intends to apply the net proceeds from the sale of the additional ADSs on a pro rata basis to the uses identified in the base offering [3]. Group 3: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases, with its lead drug candidate, obefazimod (ABX464), currently in Phase 3 clinical trials for ulcerative colitis [7].

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

当地时间7月23日，美股三大指数集体高开，但纳指随后一度翻绿，截至发稿，道指涨0.5%，纳指微涨 0.07%，标普500指数涨0.27%。 个股方面，法国生物技术公司Abivax一度大涨近600%，此前该公司报告了其口服溃疡性结肠炎治疗药物在后 期试验中取得了强劲成果。 此外，随着华尔街投机情绪升温，继百货公司股 科尔士百货 、房地产科技公司OpenDoor受到散户投资者追捧 之后，甜甜圈连锁品牌 Krispy Kreme 、运动相机制造商 GoPro 等加入 "迷因股 （Meme股，通常指散户抱团 股） " 狂欢。 中概股继续强势，纳斯达克中国金龙指数一度涨近1.4%。宏利营造一度涨超100%，脑再生一度涨超30%。 中概股强势 上天天基金APP搜索【777】注册即可 领500元券包，优选基金10元起投！限量发放！先到先得！ 中概股，继续大涨。 Abivax暴涨 法国生物技术公司Abivax暴涨，截至发稿涨574.9%。 公开资料显示，Abivax是一家专注于慢性炎症疾病的法国生物技术公司，总部位于巴黎。 中概股表现强势，截至发稿，纳斯达克中国金龙指数涨约1%。 热门中概股方面，万得中概科技龙头指数涨近2% ...

智通财经7月24日电，早盘创新药概念反复活跃，键凯科技涨超10%，南京新百2连板，联环药业、微芯 生物、迪哲医药、舒泰神、凯莱英等跟涨。消息面上，法国胃肠道药物开发商Abivax美股收盘暴涨 586%。该公司此前公布了其核心药物、口服小分子药obefazimod针对中重度活动性溃疡性结肠炎 （UC）的III期ABTECT-1和ABTECT-2试验的积极诱导期结果。 创新药概念反复活跃 键凯科技涨超10% ...

Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the launch of an approximately $400 million underwritten public offering (representing approximately €340 million) co ...

中概股，继续大涨。 当地时间7月23日，美股三大指数集体高开，但纳指随后一度翻绿，截至发稿，道指涨0.5%，纳指微涨 0.07%，标普500指数涨0.27%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | DJI | 道琼斯工业指数 | 44723.24 | 220.80 | 0.50% | | IXIC | 纳斯达克指数 | 20908.24 | 15.55 | 0.07% | | SPX | 标普500 | 6326.52 | 16.90 | 0.27% | 个股方面，法国生物技术公司Abivax一度大涨近600%，此前该公司报告了其口服溃疡性结肠炎治疗药物 在后期试验中取得了强劲成果。 此外，随着华尔街投机情绪升温，继百货公司股科尔士百货 、房地产科技公司OpenDoor受到散户投资 者追捧之后，甜甜圈连锁品牌 Krispy Kreme 、运动相机制造商 GoPro 等加入 "迷因股（Meme股，通常 指散户抱团股）" 狂欢。 中概股继续强势，纳斯达克中国金龙指数一度涨近1.4%。宏利营造一度涨超100%，脑再生一度涨超 30 ...

一则利好消息突然引爆。 7月23日晚间，美股开盘后，生物技术公司Abivax股价一度暴涨超596%。该公司宣布，口服新药Obefazimod在 溃疡性结肠炎III期诱导试验中取得积极结果，并计划2026年下半年向美国食品药品监督管理局（FDA）提交申 请。 值得注意的是，在美股散户投资者疯狂爆炒"网红股"的背景下，多家华尔街机构发出警告称，预计美股市场将 很快回调。其中，高盛、Evercore ISI、Stifel、太平洋投资管理公司和汇丰银行等机构表示，美股短期存在调 整的风险。 突然暴涨 北京时间7月23日晚间，美股三大指数集体高开，随后窄幅震荡，截至22:50，道指涨0.43%，纳指涨0.11%，标 普500指数涨0.28%。 热门股方面，在美股上市的法国生物技术公司Abivax股价盘初一度暴涨超596%，截至券商中国记者发稿，涨 幅仍高达560%。 消息面上，Abivax宣布，其首创新型口服miR-124增强剂Obefazimod在中度至重度溃疡性结肠炎的ABTECT 8 周诱导试验中取得积极的III期结果。公司还称，准备在2026年下半年向FDA提交新药申请。 有分析称，Abivax有望成为美股创新 ...

中概股，继续大涨。 当地时间7月23日，美股三大指数集体高开，但纳指随后一度翻绿，截至发稿，道指涨0.5%，纳指微涨 0.07%，标普500指数涨0.27%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | DJI | 道琼斯工业指数 | 44723.24 | 220.80 | 0.50% | | IXIC | 纳斯达克指数 | 20908.24 | 15.55 | 0.07% | | SPX | 标普500 | 6326.52 | 16.90 | 0.27% | 个股方面，法国生物技术公司Abivax一度大涨近600%，此前该公司报告了其口服溃疡性结肠炎治疗药物 在后期试验中取得了强劲成果。 此外，随着华尔街投机情绪升温，继百货公司股 科尔士百货 、房地产科技公司OpenDoor受到散户投资者 追捧之后，甜甜圈连锁品牌 Krispy Kreme 、运动相机制造商 GoPro 等加入 "迷因股 （Meme股，通常指 散户抱团股） " 狂欢。 中概股继续强势，纳斯达克中国金龙指数一度涨近1.4%。宏利营造一度涨超100%，脑再生一度涨超 ...

ABTECT Phase 3 Topline Readout – Analyst and Investor Webcast July 22nd, 2025 Agenda 2 3 This presentation contains information pertaining to Abivax SA ("Abivax," the "Company," "we," "our" or "us"). Joseph B Kirsner Professor In Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Director, Inflammatory Bowel Disease Center Forward Looking Statements David Rubin, MD David T. Rubin, MD, is a renowned gastroenterologist whose work is focused on new clinical trial designs, novel measures and ...

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis 50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials. Individually, the 50 mg dose demonstrated a placebo-adjusted remission rate of 19.3% (p<0.0001) in ABTECT-1 and a plac ...